SCHEMBL6034976

SCHEMBL6034976

O=C(O)Cc1cccc(Cl)c1OCc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.66
FABP5 Q01469 2/20 0.66
CXCL8 P10145 3/20 0.51
PTGER1 P34995 2/20 0.51
PTGER4 P35408 2/20 0.51
PTGER3 P43115 2/20 0.51
PTGER2 P43116 2/20 0.51
CAMK2A Q9UQM7 2/20 0.51
KMT2A Q03164 2/20 0.50
TTR P02766 2/20 0.49
ADRA1A P35348 2/20 0.49
AKR1B10 O60218 1/20 0.49
UGT1A9 O60656 1/20 0.49
TRPA1 O75762 1/20 0.49
ABCB11 O95342 1/20 0.49
MT-CO2 P00403 1/20 0.49
ALB P02768 1/20 0.49
UGT1A6 P19224 1/20 0.49
UGT1A1 P22309 1/20 0.49
PTGS1 P23219 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17130535 0.88 FABP4 (0.52) FABP4FABP5PTGER1PTGER4PTGER3
SCHEMBL15610227 0.83 AKR1B1 (0.58) FABP4FABP5PTGER1PTGER4PTGER3
SCHEMBL6036164 0.83 FABP4 (0.52) FABP4FABP5PTGER1PTGER4PTGER3
SCHEMBL10591847 0.83 FABP4 (0.72) FABP4FABP5PTGER1PTGER4PTGER3
SCHEMBL6036276 0.82 CXCL8 (0.51) FABP4FABP5CXCL8PTGER1PTGER4
SCHEMBL6036130 0.82 THRA (0.54) FABP4FABP5PTGER1PTGER4PTGER3
SCHEMBL31664052 0.82 THRA (0.54) FABP4FABP5PTGER1PTGER4PTGER3
SCHEMBL12117432 0.81 HTR1A (0.49) FABP4FABP5PTGER1PTGER4PTGER3
SCHEMBL16685000 0.80 AKR1B1 (0.51) FABP4FABP5KMT2ATHRATHRB
SCHEMBL21295168 0.80 HTR1A (0.61) KMT2AADRA1APTGS1PTGS2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 FABP4 279/4885FABP5 2065/4885CXCL8 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.